Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $180.00 short put and a strike $175.00 long put offers a potential 45.35% return on risk over the next 8 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $180.00 by expiration. The full premium credit of $1.56 would be kept by the premium seller. The risk of $3.44 would be incurred if the stock dropped below the $175.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is at 61.9 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Biotech ETFs in Focus on Impressive Q2 Earnings Results
Tue, 06 Aug 2019 20:22:08 +0000
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q2 earnings results recently.
5 lsquo;Strong Buyrsquo; Dividend Stocks With High Upside
Tue, 06 Aug 2019 16:54:52 +0000
The markets are looking perilous right now, with rising trade tensions and Federal Reserve uncertainty sparking heavy selling. While there has been a flight out of stocks generally – Standard & Poor's 500-stock index is off almost 6% over the past five days – dividend stocks are gaining a little appeal.Investors were caught off guard after the Federal Reserve lowered its benchmark interest rate by a quarter-point. Some were expecting a half-point cut, and others were expecting Fed Chairman Jerome Powell to signal another quarter-point cut later in the year (he didn't). Then America's trade war with China flared up after President Donald Trump threatened a new round of tariffs, which the Chinese replied to by cutting off imports of U.S. agricultural products and momentarily letting its yuan currency slip above a key level.Dividend stocks can help smooth out returns during volatile periods like this. Morgan Stanley private wealth adviser Christopher Poch is a firm believer in dividend investing. He writes, "In over 33 years in the wealth management industry, I have seen what works for the long-term, tax paying investor. The importance of dividends and the contribution to overall total return, for new and experienced investors alike, should not be overlooked.""Not only do dividend stocks as a group have less volatility year- to- year, they outperform nondividend paying stocks over time as well," Poch writes. "Over the last 90+ years, dividends have accounted for more than 40% of the total return equation."Here are five dividend stocks that TipRanks has identified as earning a "Strong Buy" rating by Wall Street's analyst community. Each of these stocks boasts relatively high yields between 3% and 5% – well more than the broader market's current 1.9% – and are projected to gain between 17% and 65% over the next 12 months. SEE ALSO: 57 Dividend Stocks You Can Count On in 2019
Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up
Tue, 06 Aug 2019 14:19:02 +0000
Botox, Juvederm fillers, Vraylar and Ozurdex drive Allergan's (AGN) second-quarter sales, making up for loss of exclusivity on some brands and lower sales of Restasis and textured breast implants.
Looking For Growth? Take A Look At These Biotechnology Stocks
Tue, 06 Aug 2019 14:00:28 +0000
The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth.
Arrowhead Research Corp (ARWR) Q3 2019 Earnings Call Transcript
Tue, 06 Aug 2019 03:23:28 +0000
ARWR earnings call for the period ending June 30, 2019.
Also on Market Tamer…
Follow Us on Facebook